Stilianos Efstratiadis, MD
Interventional Cardiology · Rolla, MONPI 1437328556
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $25,622 of the $33,526 with a category attached, or 76.4%. It is spread thinly across 38 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $11,829 and has fallen 74.4% since, to $3,029 in 2025.
Across 479 payments — averaging $69.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$6K
- Johnson & Johnson$4K
- Philips North America LLC$4K
- Boston Scientific$3K
- Edwards Lifesciences$3K
- plus $8K from 32 others
Across 3 payments — averaging $5105.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$14K
- Boston Scientific$2K
What the payments were for
- Consulting fees$2191%
- Speaking & faculty fees$4,10012%
- Travel & lodging$3,53211%
- Food & beverage$25,62276%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 81 | $6,517 |
| Medtronic(2 entities) | 87 | $5,652 |
| Johnson & Johnson | 9 | $4,182 |
| Philips North America LLC | 35 | $3,601 |
| Boston Scientific | 38 | $3,042 |
| Edwards Lifesciences | 41 | $2,754 |
| Biotronik Inc. | 30 | $2,162 |
| Endologix LLC | 1 | $602 |
| Novartis | 29 | $511 |
| Bard Peripheral Vascular, Inc. | 8 | $463 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $398 |
| Inari Medical, Inc. | 5 | $377 |
| Shockwave Medical, Inc | 7 | $348 |
| Cardiovascular Systems Inc. | 5 | $318 |
| Asahi Intecc USA, Inc. | 4 | $304 |
| Penumbra, Inc. | 2 | $220 |
| Jenavalve Technology, Inc. | 1 | $219 |
| Abiomed | 3 | $202 |
| Siemens Medical Solutions USA, Inc. | 3 | $187 |
| Angiodynamics, Inc. | 6 | $174 |
| Livanova USA, Inc. | 2 | $148 |
| Boehringer Ingelheim | 6 | $132 |
| E.r. Squibb & Sons, L.L.C. | 8 | $129 |
| Amgen | 7 | $110 |
| AstraZeneca | 7 | $104 |
| Esperion Therapeutics, Inc. | 2 | $89 |
| Pfizer | 6 | $81 |
| Cvrx, Inc. | 5 | $81 |
| Heartflow, Inc. | 1 | $81 |
| Terumo Medical Corporation | 2 | $70 |
| Novo Nordisk | 4 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Merck | 1 | $18 |
| Zimmer Biomet | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$4,100
- Xience Sierra Coronary Stent System$1,993
- SUPERA$1,773
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,599
- ONYX FRONTIER$1,418
- Micra$1,082
- SYNERGY$693
- SYMPLICITY G3$668
- ENDOCROSS Device$602
- Torus Stent Graft System$602
- FLOWTRIEVER CATHETER, S$593
- Passeo-18$540
- Pulsar-18 T3$540
- Resolute$490
- GENERAL - STRUCTURAL HEART$470
- IGT D Coronary$457
- Trilogy 100$457
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$292
- (6571) Eagle Eye$257
- (0845) Combo Wire$257
How this compares
$33,526 in reported general payments places this provider in the 75th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $125,342 |
| EntrestoSacubitril/Valsartan | 41 | $38,785 |
| XareltoRivaroxaban | 26 | $23,233 |
| JardianceEmpagliflozin | 11 | $9,986 |
| Chlorthalidone | 104 | $1,319 |
| ClopidogrelClopidogrel Bisulfate | 112 | $1,295 |
| Metoprolol Succinate | 99 | $1,283 |
| Losartan Potassium | 175 | $1,194 |
| Prasugrel Hcl | 13 | $1,113 |
| Ranolazine ErRanolazine | 16 | $964 |
| Amiodarone Hcl | 47 | $916 |
| Cilostazol | 23 | $607 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $555 |
| Ezetimibe | 16 | $493 |
| Amlodipine Besylate | 72 | $423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $125,342133 claims |
| NovartisEntresto | $511 | $38,78541 claims |
| Johnson & JohnsonXarelto | $4,182 | $23,23326 claims |
| Boehringer IngelheimJardiance | $132 | $9,98611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Rolla
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.